Trimethobenzamide
Brand and Other Names:
Tigan
Mechanism of Action:
The mechanism of action of Tigan as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
Indications:
Tigan is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Route:
Oral
Dose:
Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.
See package insert for complete information.
Adverse Reactions:
There have been reports of hypersensitivity reactions and Parkinson-like symptoms. There have been instances of hypotension reported following parenteral administration to surgical patients. There have been reports of blood dyscrasias, blurring of vision, coma, convulsions, depression of mood, diarrhea,
disorientation, dizziness, drowsiness, headache, jaundice, muscle cramps and opisthotonos. If these occur, the administration of the drug should be discontinued. Allergic-type skin reactions have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these
symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.
Contraindication:
Use of any dosage form in patients with known hypersensitivity to trimethobenzamide is contraindicated.
Warnings and Precautions:
During the course of acute febrile illness, encephalitides, gastroenteritis, dehydration and electrolyte imbalance, especially in children and the elderly or debilitated, CNS reactions such as opisthotonos, convulsions, coma and extrapyramidal symptoms have been reported with and without use of Tigan
(trimethobenzamide hydrochloride) or other antiemetic agents. In such disorders caution should be exercised in administering Tigan, particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed
toward the restoration of body fluids and electrolyte balance, the relief of fever and relief of the causative disease process. Overhydration should be avoided since it may result in cerebral edema. The antiemetic effects of Tigan may render diagnosis more difficult in such conditions as appendicitis
and obscure signs of toxicity due to overdosage of other drugs.
See package insert for full prescribing information.